313 results on '"Scaffidi, Luigi"'
Search Results
2. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
3. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
4. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
5. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib
6. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
7. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
8. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
9. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
10. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
11. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors
12. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry
13. CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients
14. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
15. P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
16. Hymenoptera Anaphylaxis as a Clonal Mast Cell Disorder
17. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected
18. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
19. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
20. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
21. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
22. Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
23. Tryptase values in anaphylaxis and insect allergy
24. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
25. Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
26. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”
27. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
28. Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity
29. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the "GRUPPO TRIVENETO LMC".
30. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study
31. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
32. The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
33. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy
34. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
35. Successful preservation of BCR‐ABL1 protein and direct measure of kinase activity in peripheral blood of CML and Ph+ ALL patients unveil a kinase inhibitory activity present in CML cells
36. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
37. Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series
38. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors
39. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
40. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
41. Second primary malignancy in myelofibrosis patients treated with ruxolitinib
42. Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival
43. Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib
44. Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations
45. First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria
46. BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC"
47. Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
48. Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome
49. Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib
50. Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.